Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, Uganda.
HIV
antiretroviral therapy
differentiated care
modeling
viral load monitoring
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
18
04
2019
accepted:
11
09
2019
pubmed:
19
9
2019
medline:
28
4
2021
entrez:
19
9
2019
Statut:
ppublish
Résumé
After scale-up of antiretroviral therapy (ART), routine annual viral load monitoring has been adopted by most countries, but reduced frequency of viral load monitoring may offer cost savings in resource-limited settings. We investigated if viral load monitoring frequency could be reduced while maintaining detection of treatment failure. The Rakai Health Sciences Program performed routine, biannual viral load monitoring on 2489 people living with human immunodeficiency virus (age ≥15 years). On the basis of these data, we built a 2-stage simulation model to compare different viral load monitoring schemes. We fit Weibull regression models for time to viral load >1000 copies/mL (treatment failure), and simulated data for 10 000 individuals over 5 years to compare 5 monitoring schemes to the current viral load testing every 6 months and every 12 months. Among 7 monitoring schemes tested, monitoring every 6 months for all subjects had the fewest months of undetected failure but also had the highest number of viral load tests. Adaptive schemes using previous viral load measurements to inform future monitoring significantly decreased the number of viral load tests without markedly increasing the number of months of undetected failure. The best adaptive monitoring scheme resulted in a 67% reduction in viral load measurements, while increasing the months of undetected failure by <20%. Adaptive viral load monitoring based on previous viral load measurements may be optimal for maintaining patient care while reducing costs, allowing more patients to be treated and monitored. Future empirical studies to evaluate differentiated monitoring are warranted.
Sections du résumé
BACKGROUND
After scale-up of antiretroviral therapy (ART), routine annual viral load monitoring has been adopted by most countries, but reduced frequency of viral load monitoring may offer cost savings in resource-limited settings. We investigated if viral load monitoring frequency could be reduced while maintaining detection of treatment failure.
METHODS
The Rakai Health Sciences Program performed routine, biannual viral load monitoring on 2489 people living with human immunodeficiency virus (age ≥15 years). On the basis of these data, we built a 2-stage simulation model to compare different viral load monitoring schemes. We fit Weibull regression models for time to viral load >1000 copies/mL (treatment failure), and simulated data for 10 000 individuals over 5 years to compare 5 monitoring schemes to the current viral load testing every 6 months and every 12 months.
RESULTS
Among 7 monitoring schemes tested, monitoring every 6 months for all subjects had the fewest months of undetected failure but also had the highest number of viral load tests. Adaptive schemes using previous viral load measurements to inform future monitoring significantly decreased the number of viral load tests without markedly increasing the number of months of undetected failure. The best adaptive monitoring scheme resulted in a 67% reduction in viral load measurements, while increasing the months of undetected failure by <20%.
CONCLUSIONS
Adaptive viral load monitoring based on previous viral load measurements may be optimal for maintaining patient care while reducing costs, allowing more patients to be treated and monitored. Future empirical studies to evaluate differentiated monitoring are warranted.
Identifiants
pubmed: 31532827
pii: 5571546
doi: 10.1093/cid/ciz880
pmc: PMC7428397
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1017-1021Subventions
Organisme : FIC NIH HHS
ID : D43 TW010557
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : PEPFAR
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Clin Infect Dis. 2014 Feb;58(3):407-12
pubmed: 24218101
Trop Med Int Health. 2015 Nov;20(11):1462-1472
pubmed: 26146863
AIDS. 2009 Mar 27;23(6):697-700
pubmed: 19209067
AIDS. 2013 Jun 1;27(9):1483-92
pubmed: 23462219
PLoS Med. 2013 Aug;10(8):e1001494
pubmed: 23940461
AIDS. 2011 Jun 1;25(9):1143-51
pubmed: 21505319
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Clin Microbiol. 2014 Sep;52(9):3377-83
pubmed: 25031444
Clin Infect Dis. 2007 Jan 1;44(1):128-34
pubmed: 17143828
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):74-8
pubmed: 23774877
Lancet HIV. 2018 Jan;5(1):e8-e9
pubmed: 29290227
Trop Med Int Health. 2012 Sep;17(9):1152-5
pubmed: 22487689